SINO BIOPHARMACEUTICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.77 HKD | +1.09% |
|
+18.38% | -20.17% |
| 04-25 | Sino Biopharm Completes Phase I Study of Hepatitis B Drug | MT |
| 04-22 | Lull in Geopolitical Tensions Lifts Asian Stock Markets | MT |
| Sales 2023 | 26.2B 3.62B 28.31B 290B | Sales 2024 * | 29.11B 4.02B 31.45B 322B | Capitalization | 47.02B 6.49B 50.8B 520B |
|---|---|---|---|---|---|
| Net income 2023 | 2.33B 322M 2.52B 25.77B | Net income 2024 * | 2.83B 390M 3.06B 31.25B | EV / Sales 2023 | 2.21 x |
| Net cash position 2023 * | 2.45B 338M 2.65B 27.07B | Net cash position 2024 * | 4.29B 591M 4.63B 47.36B | EV / Sales 2024 * | 1.47 x |
| P/E ratio 2023 |
25.1
x | P/E ratio 2024 * |
16.7
x | Employees | 25,806 |
| Yield 2023 * |
2.25% | Yield 2024 * |
2.14% | Free-Float | 51.81% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +1.09% | ||
| 1 week | +18.38% | ||
| Current month | -8.28% | ||
| 1 month | -10.93% | ||
| 3 months | -4.15% | ||
| 6 months | +4.14% | ||
| Current year | -20.17% |
1 week
2.41
2.81
1 month
2.293.08
Current year
2.293.49
1 year
2.294.41
3 years
2.299.69
5 years
2.2911.24
10 years
1.7011.24
| Managers | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 29 | 22/10/19 |
Ping Tse
FOU | Founder | 72 | 01/02/00 |
Chun Ling Li
DFI | Director of Finance/CFO | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ping Tse
FOU | Founder | 72 | 01/02/00 |
| Director/Board Member | 60 | 31/12/04 | |
Hsin Tse
BRD | Director/Board Member | 54 | 31/07/95 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.40% | 2 M€ | -16.59% | - | |
| 2.02% | 4 M€ | -27.92% | ||
| 0.82% | 3 M€ | -0.84% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.77 | +1.09% | 39,487,700 |
| 25/04/24 | 2.74 | +2.24% | 90,192,910 |
| 24/04/24 | 2.68 | +3.88% | 78,914,760 |
| 23/04/24 | 2.58 | +1.57% | 49,984,610 |
| 22/04/24 | 2.54 | +8.55% | 94,155,090 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows:
- chemical medicine products and biopharmaceutical drugs (97.6%);
- other (2.4%).
Sector
Pharmaceuticals
Calendar
10/06/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
2.564
CNY
Average target price
4.32
CNY
Spread / Average Target
+68.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.17% | 6.49B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 1177 Stock
